<table>
<thead>
<tr>
<th>DRUGS</th>
<th>6H</th>
<th>3HP</th>
<th>3HR</th>
<th>4R</th>
<th>1HP</th>
<th>H+B6+CPT (q-TIB)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Isoniazid</td>
<td></td>
<td>Isoniazid + Rifapentine</td>
<td>INH+ Rifampicin</td>
<td>Rifampicin</td>
<td>Isoniazid + Pyridoxine + cotrimoxazole</td>
<td></td>
</tr>
<tr>
<td>DURATION (MONTHS)</td>
<td>6</td>
<td>3</td>
<td>3</td>
<td>4</td>
<td>1</td>
<td>6</td>
</tr>
<tr>
<td>INTERVAL</td>
<td>Daily</td>
<td>Weekly</td>
<td>Daily</td>
<td>Daily</td>
<td>Daily</td>
<td></td>
</tr>
<tr>
<td>DOSES</td>
<td>182</td>
<td>12</td>
<td>84</td>
<td>120</td>
<td>26</td>
<td>182</td>
</tr>
<tr>
<td>PILL BURDEN PER DOSE</td>
<td>1 (182)</td>
<td>9 singles (108)</td>
<td>3 with FDC (36)</td>
<td>3 (252)</td>
<td>2 (240)</td>
<td>5 (140)</td>
</tr>
</tbody>
</table>

**PILL BURDEN PER DOSE (total number of pills for average adult)**

- **6H**: 1 (182)
- **3HP**: 9 singles (108)
- **3HR**: 3 with FDC (36)
- **4R**: 3 (252)
- **1HP**: 2 (240)
- **H+B6+CPT (q-TIB)**: 5 (140)

**COST** (60)

- **6H**: $3.50
- **3HP**: $10.60 (for 12-15kg child)
- **3HR**: $24
- **4R**: RPT+INH- $27 for singles, $26 for FDC+RPT single
- **1HP**: $12

**CHILDREN**

- Yes all ages; child-friendly (dispersible) formulation available, preferred in HIV+ve children on LPV-RTV, NVP, or DTG
- ≥ 2 years (and at least 20 kg), no child friendly formulation available
- All ages; child-friendly (dispersible) formulation available and recommended up to 35 kg weight
- All ages; no child-friendly formulation available, no formulation available for infants <6kg weight
- All ages; no child-friendly formulation available, no formulation available for infants <6kg weight
- No rifapentine dosing available until 13 years of age
- All ages; need to split scored adult tablet, lower dose pills suitable for children not available

**PREGNANT WOMEN**

- Not recommended in Malawi according to TPT guidelines
- Not recommended in Malawi according to TPT guidelines
- Safe for use
- Maybe be safe, although no safety or efficacy data available specifically in this population
- Not known
- Safe for use preferred option in PLHIV

**INTERACTIONS WITH ART**

- No restriction
- Contraindicated: All PIs, NVP/most NNRTIs, TAF
- Use: TDF, EFV (600mg), DTG, RAL
- Contraindicated: All PIs, NVP/most NNRTIs, TAF
- Use: TDF, EFV (600mg)
- Contraindicated: All PIs, NVP/most NNRTIs, TAF
- Use: TDF, EFV (600mg)
- Contraindicated: All PIs, NVP/most NNRTIs, TAF
- Use: TDF, EFV (600mg)
- No restriction

**SIDE-EFFECT PROFILE/TOXICITY**

- Hepatotoxicity (more), peripheral neuropathy, rash, gastrointestinal (GI) upset
- Flu-like syndrome, hypersensitivity reactions, GI upset, Orange discoloration of body fluids, rash, hepatotoxicity (less)
- Hypersensitivity reactions, hepatotoxicity (less), rash, GI upset, hypophosphoribonucleic acid (less) hypophosphoribonucleic acid, Orange discoloration of body fluids
- Rash, GI upset, hepatotoxicity (less), hypophosphoribonucleic acid, Orange discoloration of body fluids
- Hepatotoxicity (more), hypersensitivity reaction, rash, GI upset, Orange discoloration of body fluids
- Hepatotoxicity, rash, GI upset

**ABSORPTION**

- Best absorbed on an empty stomach; up to 50% reduction in peak concentration with a fatty meal
- Oral rifapentine bioavailability is 70% (not HP). Peak concentration increased if given with a meal.
- Rifampicin absorption is rapid but may be delayed or decreased by high-fat meals.
- Same as 3HP
- Same as 6H

**AVAILABILITY IN MALAWI**

- available
- available
- available but not recommended
- not available
- not available